Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Hemostemix Inc (HEM.VN)

Hemostemix Inc (HEM.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,490
  • Shares Outstanding, K 89,792
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,235 K
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade HEM.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $0.00 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.050 unch
on 04/19/24
0.070 -28.57%
on 03/20/24
-0.025 (-33.33%)
since 03/19/24
3-Month
0.050 unch
on 04/19/24
0.110 -54.55%
on 02/12/24
-0.025 (-33.33%)
since 01/19/24
52-Week
0.050 unch
on 04/19/24
0.175 -71.43%
on 08/10/23
-0.120 (-70.59%)
since 04/19/23

Most Recent Stories

More News
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.

Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix Clarifies its October 3, 2023 News Release

Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease

Calgary, Alberta--(Newsfile Corp. - October 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that Stem Cell Research & Therapy published the Company's seventh peer...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000

Calgary, Alberta--(Newsfile Corp. - October 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix Closed $320,125 Private Placement

Calgary, Alberta--(Newsfile Corp. - October 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it closed its private placement of $320,125, the sale of approximately...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix Announces Private Placement

Calgary, Alberta--(Newsfile Corp. - September 27, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a new private placement of $325,125, the sale of approximately 2.7...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces

Calgary, Alberta--(Newsfile Corp. - September 12, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has been...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications

Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has applied for grant funding...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement

Calgary, Alberta--(Newsfile Corp. - August 14, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that on August 10, 2023 it received a final cost award from the International...

HMTXF : 0.0371 (-17.74%)
HEM.VN : 0.050 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.050
2nd Resistance Point 0.050
1st Resistance Point 0.050
Last Price 0.050
1st Support Level 0.050
2nd Support Level 0.050
3rd Support Level 0.050

See More

52-Week High 0.175
Fibonacci 61.8% 0.127
Fibonacci 50% 0.112
Fibonacci 38.2% 0.098
Last Price 0.050
52-Week Low 0.050

See More

Business Summary

Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar